Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastiano Buti

Showing results (211-220 of 336) with videos related to

Pageof 34
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 26, 2023
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO networkEmilio Francesco Giunta, Silvia De Padova, Shobana Anpalakhan, et al.
Oncotarget|December 17, 2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysisDaniele Santini, Raffaele Ratta, Francesco Pantano, et al.
Clinical Genitourinary Cancer|May 28, 2018
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?Roberto Iacovelli, Ugo De Giorgi, Luca Galli, et al.
Annals of Surgical Oncology|December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitorsMatteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Urologic Oncology|April 3, 2019
The effect of a treatment delay on outcome in metastatic renal cell carcinomaRoberto Iacovelli, Luca Galli, Ugo De Giorgi, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Lancet (London, England)|February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Immunotherapy|August 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumabAlessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
Targeted Oncology|September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 TrialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Pageof 34

Showing results (211-220 of 336) with videos related to

Sort By:
Pageof 34
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 26, 2023
The role of the caregiver in older patients with advanced prostate cancer: results from the ADHERE Prospective Study of the Meet-URO networkEmilio Francesco Giunta, Silvia De Padova, Shobana Anpalakhan, et al.
Oncotarget|December 17, 2017
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysisDaniele Santini, Raffaele Ratta, Francesco Pantano, et al.
Clinical Genitourinary Cancer|May 28, 2018
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?Roberto Iacovelli, Ugo De Giorgi, Luca Galli, et al.
Annals of Surgical Oncology|December 5, 2014
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitorsMatteo Santoni, Alessandro Conti, Stefano Partelli, et al.
Urologic Oncology|April 3, 2019
The effect of a treatment delay on outcome in metastatic renal cell carcinomaRoberto Iacovelli, Luca Galli, Ugo De Giorgi, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Lancet (London, England)|February 12, 2023
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Immunotherapy|August 19, 2024
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumabAlessandra Damassi, Malvina Cremante, Alessio Signori, et al.
Minerva Urology and Nephrology|December 13, 2022
A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA ScoreGiuseppe Fornarini, Sara E Rebuzzi, Sebastiano Buti, et al.
Targeted Oncology|September 2, 2023
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 TrialRobert J Motzer, Paul Russo, Viktor Grünwald, et al.
Pageof 34